Skin levels of advanced glycation end products in correlation with periodontal conditions - a pilot study

皮肤中晚期糖基化终产物水平与牙周状况的相关性——一项初步研究

阅读:1

Abstract

BACKGROUND: Although associations between periodontitis and metabolic diseases are established, published data about the correlation of advanced glycation end products (AGEs) and periodontal inflammation are scarce. The aim of the pilot study was to assess the AGE-levels in the skin of patients with gingival (GI: bleeding on probing (BOP) positive, no periodontal pockets), or periodontal inflammation (PE + : BOP-positive with periodontal pockets), or individuals with a history of periodontitis but no signs of current inflammation (PE-: BOP-negative with clinical attachment loss) to evaluate a potential role of AGEs as a biomarker for disease severity and risk of metabolic comorbidities in patients with GI or PE. METHODS: After an oral examination a total of 168 patients (healthy or with control systemic conditions e.g. diabetes) were classified into a GI (n = 68), PE + (n = 64) and PE- (n = 36) group. AGE levels were measured non-invasively on the skin of the inner forearm using a point-of-care AGE-reader. Cardiovascular (CV) risk was assessed based on numerical AGE read-out in the skin and diabetes risk was determined using the Finnish-Diabetes-Risk-Score (FINDRISC) questionnaire. RESULTS: Significantly higher AGE levels were found in PE (2.1(0.6)) versus GI (1.7(0.6) (p < 0.001), whereas no significant association could be identified between the CV risk in PE versus GI (p = 0.196). A subgroup analysis in PE identified a positive association for patients with current gingival inflammation (PE +) and higher CV-risk (p = 0.031). The FINDRISC was higher in PE (10.1(5.1)) compared to GI (6.1(4.9)) (p < 0.001). CONCLUSION: Current inflammation in PE is associated with increased CV risk based on AGE levels of the skin. The AGE Reader may serve as a non-invasive screening tool in dental practice to support early CV-risk assessment and interdisciplinary prevention strategies. TRIAL REGISTRATION: The study was retrospectively registered in the DRKS—German Clinical Trials Register (https://www.drks.de) with the registration-ID DRKS00031545 (23/03/2023).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。